Close

Form 8-K HAEMONETICS CORP For: Nov 03

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. TSM
3. ISRG
4. INFY
5. SNV
6. TSLA
7. SPY
8. SMCI
9. PPG
10. JWN


November 3, 2014 6:14 AM EST
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
�
FORM�8-K
�
CURRENT REPORT
Pursuant to Section�13 OR 15(d)�of The Securities Exchange Act of 1934
�Date of Report (Date of earliest event reported) � November�3, 2014
�HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
�
Massachusetts
�
001-14041
�
04-2882273
(State or other jurisdiction
of incorporation)
�
(Commission
File Number)
�
(I.R.S. Employer
Identification No.)
�
400 Wood Road
�
02184
(Address of principal executive offices)
�
Zip code
�
Registrant's telephone number, including area code� 781-848-7100
�
(Former name or former address, if changed since last report.)
��
�
Check the appropriate box below if the Form�8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
�
�
o
Written communications pursuant to Rule�425 under the Securities Act (17 CFR 230.425)
�
�
o
Soliciting material pursuant to Rule�14a-12 under the Exchange Act (17 CFR 240.14a-12)
�
�
o
Pre-commencement communications pursuant to Rule�14d-2(b)�under the Exchange Act (17 CFR 240.14d-2(b))
�
�
o
Pre-commencement communications pursuant to Rule�13e-4(c)�under the Exchange Act (17 CFR 240.13e-4(c))
�
�





Item 2.02�������������� RESULTS OF OPERATIONS AND FINANCIAL CONDITION
�
On November�3, 2014, Haemonetics Corporation (the Company) issued a press release announcing financial results for the second quarter ended September�27, 2014.� A copy of the release is furnished with this report as exhibit 99.1.
�
The information in this current report on Form�8-K and the exhibit attached hereto shall not be deemed filed for the purposes of Section�18 of the Securities and Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
�
Item 9.01�������������� FINANCIAL STATEMENTS AND EXHIBITS

99.1: Press Release of Haemonetics Corporation dated November�3, 2014 announcing financial results for the second quarter ended September�27, 2014.
�


�
SIGNATURES
�
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
�
�
�
�
�
�
HAEMONETICS CORPORATION
�
(Registrant)
�
�
�
�
�
�
Date: November 3, 2014
By:
/s/ Christopher Lindop
�
�
Christopher Lindop, Chief Financial Officer and
�
�
Executive Vice President Business Development




�
�
�
Exhibit 99.1
�
�
�
News Release
�
�
�
�
FOR RELEASE:
�
CONTACT:
Date
November�3, 2014
�
Gerry Gould, VP-Investor Relations
Time
6:00 am Eastern
�
Tel. (781) 356-9402
�
�
�
�
�
�
Alt. (781) 356-9613

Haemonetics Reports 2nd Quarter Fiscal 2015 Revenue of $228 Million and Adjusted EPS of $0.47; Reaffirms Revenue and Earnings Guidance

Braintree, MA, November 3, 2014 - Haemonetics Corporation (NYSE: HAE) today reported second quarter fiscal 2015 revenue of $227.6 million, down 3.5%. In constant currency, revenue declined 2.6% in the quarter. The Company reported second quarter GAAP net income of $7.5 million and GAAP net income per share of $0.14. Exclusive of transformation, restructuring and deal amortization expenses detailed below, adjusted net income was $24.3 million and adjusted earnings per share were $0.47, both down 29%.1

First half fiscal 2015 revenue was $452.1 million, down 1%, and flat in constant currency. The Company reported first half GAAP net income of $3.8 million and GAAP net income per share of $0.07. Exclusive of transformation, restructuring and deal amortization expenses detailed below, adjusted net income was $44.1 million and adjusted earnings per share were $0.85, both down 24%.1


2Q FISCAL 2015 HIGHLIGHTS

"
Continued solid constant currency revenue increases in growth drivers
�
7% growth in plasma disposables revenue
�
23% growth in TEG� diagnostics disposables revenue
�
7% growth in China disposables revenue
"
Key new product advances
�
Next generation Plasma software receives 510(k) approval; long term contract signed with first customer
�
Next generation BloodTrack� software receives 510(k) approval
�
BloodTrack� HaemoBank" introduced at 2014 AABB Annual Meeting
"
Long term saline and sodium citrate solutions supply contract signed with CSL Plasma, Inc.
"
$8 million of share repurchases in the quarter
"
Value Creation and Capture (VCC) initiatives progressing on schedule





GROWTH DRIVERS UPDATE - Plasma, TEG�, Emerging Markets

Combined disposables revenue increase for growth drivers was 11% in the first half of fiscal 2015, and 9% when adjusted for the impact of a favorable Plasma comparison resulting from the acquisition of the Companys Australian plasma distributor in the first half of fiscal 2014. In the second quarter, orders in emerging markets were impacted by labeling changes which limited disposables revenue growth in the combined growth drivers to 5%. These labeling changes are expected to be completed within fiscal 2015, benefiting second half revenue growth.

Brian Concannon, Haemonetics President and CEO, stated: Our growth drivers represent 57% of our disposables revenue, growing 9% in the first half of fiscal 2015 when adjusted for the prior years Plasma comparison.

We expect double-digit revenue increases in our growth drivers to continue through fiscal years 2015 and 2016, positioning us well to extend a five year history of double digit compounded annual growth. For the remainder of fiscal 2015, this growth will continue to be offset by headwinds including the impact of blood management practice improvements, as well as lower share and lower pricing in our U.S. whole blood business. We expect these headwinds to moderate in fiscal 2016.

SECOND QUARTER AND FIRST HALF 2015 REVENUE ELEMENTS

Plasma

Plasma disposables revenue was $80.4 million in the second quarter, up $4.6 million, or 6% on a reported basis and 7% in constant currency. North America Plasma disposables revenue was up 12%, as collection volumes continued to benefit from a robust end user market for plasma-derived biopharmaceuticals. Excluding the favorable impact of the distribution model change in Australia last year, Plasma revenue growth was 11% in the first half of fiscal 2015.

Blood Center

Platelet disposables revenue was $39.4 million in the quarter, down 1% on a reported basis and up 4% on a constant currency basis. First half constant currency revenue growth of 9% was attributable to strong demand in the emerging markets.

Red cell disposables revenue was $10.2 million in the second quarter, flat with the prior year, and $20.4 million in the first half, up 1% over the prior year.




Whole blood disposables revenue was $33.7 million in the second quarter of fiscal 2015, down $13.5 million or 29%, and $71.7 million in the first half, down $26.8 million or 27%. Previously disclosed market share losses, pricing and the termination of an OEM supply contract negotiated at the time of the whole blood acquisition contributed to the first half decline. These headwinds will anniversary by the first quarter of fiscal 2016. Declines in North American transfusion rates of roughly 10% contributed approximately $5 million of the first half decline. This trend is expected to continue through fiscal 2015 and moderate in fiscal 2016.

Hospital

Surgical disposables revenue was $15.7 million in the second quarter, down 4% as reported and down 2% on a constant currency basis. First half fiscal 2015 surgical disposals revenue of $31.3 million was down 4% reported and 2% in constant currency. Strength in the emerging markets was offset by declines in the developed markets in the second quarter and first half.

Disposables revenue from the OrthoPAT� orthopedic perioperative autotransfusion system was $4.9 million for the quarter, down $1.4 million or 22%. First half OrthoPAT� revenue was $10.3 million, down $2.3 million or 18%. Market trends toward the adoption of tranexamic acid to prevent post-operative blood loss continued to lessen hospital use of OrthoPAT� disposables.

Diagnostics disposables revenue was $10.0 million for the quarter and $19.6 million in the first half of fiscal 2015, up $2.1 million and $4.1 million respectively, both up 26% on a reported basis and 23% in constant currency. Strength continued in both new and existing accounts in North America and China. The TEG� Thromboelastograph� Hemostasis Analyzer installed base increased by 16% in the trailing 12 months, positioning the TEG� business for continued double-digit disposables revenue growth.

Software and Equipment

Software Solutions revenue was $18.1 million in the first quarter, up $1.0 million, and $36 million in the first half, up $2 million, a 6% increase in both periods. BloodTrack� in the U.K. and North America drove this growth and the pipeline for blood management software opportunities remains strong.

The Company is optimistic about continued revenue growth from software solutions and cited a number of recent advances. First, the next generation plasma software gained 510(k) approval during the second quarter of fiscal 2015. Following this approval, the Company completed a long-term contract with a



customer for the customization of the new software during fiscal 2016, to be used in their collection facilities in the future.

Additionally, the Company announced 510(k) approval of a cross donation check system for the plasma collection industry. This automated system, requested by the Plasma Protein Therapeutics Association, will enhance the plasma suitability assessment process. This will enable plasma collectors to track and check donor viability using a single reliable source. Initial software revenue is expected to be realized in fiscal 2016.

Finally, the Company announced that its next generation BloodTrack� software gained 510(k) approval during the second quarter. This software has been incorporated into a new BloodTrack� HaemoBank" device, forming a powerful new blood management tool. This represents the first new point-of-care blood management technology developed in the Companys ongoing strategic OEM partnership with Helmer Scientific. This new software and hardware combination was recently introduced at trade shows in the U.K. and U.S. Its limited market release is expected late in the second half of fiscal 2015.

Equipment and other revenue was $15.2 million, up $0.3 million or 2%. Equipment revenue is influenced by timing of tenders and capital budgets. The installed base of equipment, including devices sold and placed for use with customers, increased sequentially 2% in the quarter, 3% in the first half of fiscal 2015 and 7% in the last 12 months.
�
Geographic

In the second quarter of fiscal 2015, Haemonetics announced revenue declines of 1% in North America, 2% in Europe, 3% in Asia Pacific and 18% in Japan on a reported basis. On a constant currency basis, the Company had revenue declines of 5% in Europe, 5% in Asia Pacific and 5% in Japan.

In North America, strength in Plasma and TEG� diagnostics was offset by declines in the Blood Center business. Order timing associated with labeling changes contributed to declines in Europe and whole blood revenue declined in Asia Pacific. Weakness in Japan was attributable to the Yen exchange rate, which contributed 13 percentage points of the decline in the second quarter.










OPERATING RESULTS
�
Adjusted gross profit was $111.0 million, down $12.3 million from the prior year second quarter and included a $2.7 million unfavorable currency impact. Adjusted gross margin was 48.8%, down 350 basis points. As expected, adjusted gross margin improvement, driven by productivity programs including VCC initiatives, continued to be more than offset by lower U.S. whole blood disposables pricing, lower volume in certain manufacturing facilities, product mix and currency.

Savings from VCC programs and other identified cost reductions are expected to contribute to increased earnings in the second half of fiscal 2015.

Adjusted operating expenses were $75.9 million in the quarter, up $1.5 million or 2% over the prior year second quarter. Critical investments continued and were offset by organizational and corporate administrative cost reductions.

In the second quarter, adjusted operating income was $35.1 million, down $13.9 million or 28.3%, reflecting the gross margin headwinds cited. Adjusted operating margin in the quarter was 15.4%, down 540 basis points, as gross margin pressures more than offset cost savings.

Adjusted interest expense on loans was $2.0 million. The adjusted income tax rate was 25.7% compared with 26.2% in the prior year second quarter.

Mr. Concannon said: We continue to see fiscal 2015 as a transitional year, with revenue and earnings below fiscal 2014 levels. We are encouraged with progress in the first half toward our revenue targets and cost reduction programs. Revenue growth in our hospital business, resolution of emerging market order timing and a concurrent ramp in cost savings will contribute to the expected step-up in earnings in the second half of the year. We reaffirm our fiscal 2015 revenue and earnings guidance.

We recently entered into a long-term contract with CSL Plasma, Inc. to supply saline and sodium citrate solutions needed in their plasma collection process. Shipments will commence in fiscal 2016.

The opportunity to serve this Plasma customer, combined with the recent software advances in our Plasma and hospital businesses, enables us to be confident in reiterating our expectation of returning to growth in fiscal 2016 and beyond.








BALANCE SHEET AND CASH FLOW

Cash on hand was $130 million, a decrease of $62 million during the first half of fiscal 2015. The Company reported free cash flow, before transformation and restructuring costs, of $28 million, a decrease of $20 million compared with the first half of fiscal 2014.

During the first half of fiscal 2015, the Company utilized $65 million of cash before $12 million of cash tax benefits, to fund VCC and other restructuring initiatives, $34 million to repurchase shares in the open market and $9 million to repay debt.

FISCAL 2015 SHARE REPURCHASE PROGRAM

The Company repurchased 1,034,800 shares in the open market at an average price of $32.89, for a total spend of $34 million in the first half of fiscal 2015. As previously announced, the Board of Directors approved the repurchase of up to $100 million of shares in the open market.

VALUE CREATION & CAPTURE ACTIVITIES
�
Plans to pursue identified Value Creation & Capture (VCC) opportunities, designed principally to transform the Companys manufacturing and distribution operations, and to support its productivity and commercial excellence initiatives, continue to progress according to schedule.

VCC investments are still expected to approximate $160 million in total and to generate approximately $60-$65 million of annual cost savings by fiscal 2018. The planned investments and expected benefits are summarized in a schedule posted to the Companys Investor Relations website at http://phx.corporate-ir.net/phoenix.zhtml?c=72118&p=irol-guidance.

FISCAL 2015 GUIDANCE

Overall fiscal 2015 revenue is reaffirmed at a decline of 0-2%, with $40-$50 million of revenue growth from identified growth drivers more than offset by $50-$55 million of revenue headwind from net volume and pricing declines in the U.S. blood center business and weakness in the Japanese Yen.

The Company reaffirms its guidance for 7-9% growth in Plasma disposables, a decline in blood center revenue of 10-12%, hospital disposables growth of 4-6% and Software Solutions growth of 2-4%.




The Company reaffirms its full year expectations for adjusted gross margin of approximately 50%, adjusted operating income of $140-$150 million, and adjusted earnings per share in the range of $1.85 to $1.95. Previous free cash flow guidance of approximately $120-$130 million, before funding restructuring and capital investment for transformation activities, is adjusted to approximately $100-$110 million. Elements impacting this change include higher solutions inventories and capital expenditures required to meet the needs of the new saline and sodium citrate contract announced this morning, and a ramp-up of Plasma devices to support anticipated growth.

More information on fiscal 2015 guidance, including income statement scenarios underlying the lower and upper ends of the adjusted earnings per share guidance range, can be found in the Investor Relations section of our web site at http://www.haemonetics.com.1 �

FISCAL 2016 PRELIMINARY OUTLOOK

The Company reiterates its expectations of returning to a mid-single digit revenue growth rate and double digit adjusted operating income and earnings per share growth rates in fiscal 2016. The VCC investments are on track to be completed in fiscal 2016.

ADJUSTMENTS TO REPORTED EARNINGS
�
In total, $15 million of pre-tax charges comprised of $14 million of VCC transformation and $1 million of other restructuring activities were excluded from adjusted earnings in the second quarter of fiscal 2015. The Company excluded $19 million of pre-tax integration, restructuring, transformation and transaction costs from adjusted earnings in the second quarter of fiscal 2014.

$38 million of pre-tax charges comprised of $34 million of VCC transformation and $4 million of other restructuring activities were excluded from adjusted earnings in the first half of fiscal 2015. The Company excluded $52 million of pre-tax integration, restructuring, transformation and transaction costs from adjusted earnings in the first half of fiscal 2014.

The Company also excludes acquisition related amortization expenses from its adjusted operating income and earnings per share. Excluded from second quarter adjusted earnings was acquisition related amortization of $8 million in fiscal 2015 and $7 million in fiscal 2014, or $0.10 and $0.09 per share, respectively.





Excluded from first half adjusted earnings was acquisition related amortization of $15 million in fiscal 2015 and $14 million in fiscal 2014, or $0.20 and $0.19 per share, respectively. For the full fiscal year 2015, acquisition related amortization is expected to approximate $31 million or $0.41 per share.

CONFERENCE CALL

Haemonetics will host a webcast to discuss the second quarter and first half fiscal 2015 results today at 8:00 am Eastern time. Interested parties can participate at: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=5170168.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

FORWARD LOOKING STATEMENTS

This release contains forward-looking statements that involve risks and uncertainties, including the effects of disruption from the manufacturing transformation making it more difficult to maintain relationships with employees and timely deliver high quality products, unexpected expenses incurred during our Value Creation and Capture program, technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, demand for whole blood and blood components, product quality, market acceptance, regulatory uncertainties, including in the receipt or timing of regulatory approvals, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers ordering patterns including single-source tenders, the effect of industry consolidation as seen in the plasma and blood center markets, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission.




The foregoing list should not be construed as exhaustive.

Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.�Information set forth in this press release is current as of today and the Company undertakes no duty or obligation to update this information.����

1A reconciliation of GAAP to adjusted financial results is included at the end of the financial sections of this press release as well as on the web at http://www.haemonetics.com. �





Haemonetics Corporation Financial Summary
(Data in thousands, except per share data)
Consolidated Statements of Income for the Second Quarter of FY15 and FY14
�
�
�
�
�
�
�
�
�
9/27/2014
�
9/28/2013
�
% Inc/(Dec)
�
�
As Reported
�
As Reported
�
vs Prior Year
�
�
(unaudited)
�
�
Net revenues
$
227,580

�
$
235,755

�
(3.5)%
Gross profit
108,114

�
119,884

�
(9.8)%
�
�
�
�
�
�
�
�
R&D
10,938

�
14,946

�
(26.8)%
�
S,G&A
84,769

�
81,508

�
4.0%
Operating expenses
95,707

�
96,454

�
(0.8)%
�
�
�
�
�
�
�
Operating income
12,407

�
23,430

�
(47.0)%
�
�
�
�
�
�
�
Interest and other expense, net
(2,645
)
�
(2,542
)
�
4.1%
�
�
�
�
�
�
�
Income before taxes
9,762

�
20,888

�
(53.3)%
�
�
�
�
�
�
�
Tax expense
2,275

�
4,340

�
(47.6)%
�
�
�
�
�
�
�
Net income
$
7,487

�
$
16,548

�
(54.8)%
�
�
�
�
�
�
�
�
�
�
�
�
�
Net income per common share assuming dilution
$
0.14

�
$
0.32

�
(56.3)%
�
�
�
�
�
�
�
Weighted average number of shares:
�
�
�
�
�
�
Basic
51,391

�
51,492

�
�
�
Diluted
51,925

�
52,361

�
�
�
�
�
�
�
�
�
Profit Margins:
�
�
�
�
Inc/(Dec) vs prior year profit margin %
Gross profit
47.5
%
�
50.9
%
�
(3.4)%
R&D
4.8
%
�
6.3
%
�
(1.5)%
S,G&A
37.2
%
�
34.6
%
�
2.6%
Operating income
5.5
%
�
9.9
%
�
(4.4)%
Income before taxes
4.3
%
�
8.9
%
�
(4.6)%
Net income
3.3
%
�
7.0
%
�
(3.7)%



Haemonetics Corporation Financial Summary
(Data in thousands, except per share data)
Consolidated Statements of Income for Year-to-Date FY15 and FY14
�
�
�
�
�
�
�
�
�
9/27/2014
�
9/28/2013
�
% Inc/(Dec)
�
�
As Reported
�
As Reported
�
vs Prior Year
�
�
(unaudited)
�
�
Net revenues
$
452,068

�
$
455,297

�
(0.7)%
Gross profit
214,392

�
231,295

�
(7.3)%
�
�
�
�
�
�
�
�
R&D
26,319

�
26,155

�
0.6%
�
S,G&A
177,331

�
188,318

�
(5.8)%
Operating expenses
203,650

�
214,473

�
(5.0)%
�
�
�
�
�
�
�
Operating income
10,742

�
16,822

�
(36.1)%
�
�
�
�
�
�
�
Interest and other expense, net
(5,188
)
�
(5,183
)
�
0.1%
�
�
�
�
�
�
�
Income before taxes
5,554

�
11,639

�
(52.3)%
�
�
�
�
�
�
�
Tax expense
1,715

�
2,965

�
(42.2)%
�
�
�
�
�
�
�
Net income
$
3,839

�
$
8,674

�
(55.7)%
�
�
�
�
�
�
�
�
�
�
�
�
�
Net income per common share assuming dilution
$
0.07

�
$
0.17

�
(58.8)%
�
�
�

�
�
�
�
Weighted average number of shares:
�

�
�
�
�
�
Basic
51,567

�
51,360

�
�
�
Diluted
52,056

�
52,200

�
�
�
�
�

�
�
�
�
Profit Margins:
�

�
�
�
Inc/(Dec) vs prior year profit margin %
Gross profit
47.4
%
�
50.8
%
�
(3.4)%
R&D
5.8
%
�
5.7
%
�
0.1%
S,G&A
39.2
%
�
41.4
%
�
(2.2)%
Operating income
2.4
%
�
3.7
%
�
(1.3)%
Income before taxes
1.2
%
�
2.6
%
�
(1.4)%
Net income
0.8
%
�
1.9
%
�
(1.1)%
�
�
�
�
�
�
�



Revenue Analysis for the Second Quarter FY15 and FY14
(Data in thousands)
�
�
�
�
�
Three Months Ended
�
�
9/27/2014
�
9/28/2013
�
% Inc/(Dec)
�
�
As Reported
�
As Reported
�
vs Prior Year
�
�
(unaudited)
�
�
Revenues by geography
�
�
�
�
�
�
United States
$
124,406

�
$
125,662

�
(1.0
)%
�
International
103,174

�
110,093

�
(6.3
)%
Net revenues
$
227,580

�
$
235,755

�
(3.5
)%
�
�
�
�
�
�
�
Disposable revenues
�
�
�
�
�
�
�
�
�
�
�
�
�
Plasma disposables
$
80,355

�
$
75,734

�
6.1
�%
�
�
�
�
�
�
�
�
Blood center disposables

�

�
�
�
Platelet
39,370

�
39,884

�
(1.3
)%
�
Red cell
10,176

�
10,221

�
(0.4
)%
�
Whole blood
33,738

�
47,283

�
(28.6
)%
�
�
83,284

�
97,388

�
(14.5
)%
�
Hospital disposables
�
�
�
�
�
�
Surgical
15,661

�
16,351

�
(4.2
)%
�
OrthoPAT
4,898

�
6,262

�
(21.8
)%
�
Diagnostics
10,047

�
7,985

�
25.8
�%
�
�
30,606

�
30,598

�

�%
�
�
�
�
�
�
�
�
Total disposables revenues
194,245

�
203,720

�
(4.7
)%
�
�
�
�
�
�
�
Software solutions
18,145

�
17,120

�
6.0
�%
Equipment & other
15,190

�
14,915

�
1.8
�%
Net revenues
$
227,580

�
$
235,755

�
(3.5
)%



�
�
�
�
�
�
�
Revenue Analysis for Year-to-Date FY15 and FY14
(Data in thousands)
�
�
�
�
�
Six Months Ended
�
�
9/27/2014
�
9/28/2013
�
% Inc/(Dec)
�
�
As Reported
�
As Reported
�
vs Prior Year
�
�
(unaudited)
�
�
Revenues by geography
�
�
�
�
�
�
United States
$
245,155

�
$
247,807

�
(1.1
)%
�
International
206,913

�
207,490

�
(0.3
)%
Net revenues
$
452,068

�
$
455,297

�
(0.7
)%
�
�
�
�
�
�
�
Disposable revenues
�
�
�
�
�
�
�
�
�
�
�
�
�
Plasma disposables
$
159,582

�
$
141,070

�
13.1
�%
�
�
�
�
�
�
�
�
Blood center disposables
�
�
�
�
�
�
Platelet
77,541

�
74,330

�
4.3
�%
�
Red cell
20,422

�
20,229

�
1.0
�%
�
Whole blood
71,688

�
98,537

�
(27.2
)%
�
�
169,651

�
193,096

�
(12.1
)%
�
Hospital disposables
�
�
�
�
�
�
Surgical
31,281

�
32,441

�
(3.6
)%
�
OrthoPAT
10,279

�
12,581

�
(18.3
)%
�
Diagnostics
19,645

�
15,579

�
26.1
�%
�
�
61,205

�
60,601

�
1.0
�%
�
�
�
�
�
�
�
�
Total disposables revenues
390,438

�
394,767

�
(1.1
)%
�
�
�
�
�
�
�
Software solutions
35,883

�
33,866

�
6.0
�%
Equipment & other
25,747

�
26,664

�
(3.4
)%
Net revenues
$
452,068

�
$
455,297

�
(0.7
)%
�
�
�
�
�
�
�



Consolidated Balance Sheets
(Data in thousands)
�
�
�
�
�
�
�
As of
�
�
�
9/27/2014
�
3/29/2014
�
�
�
(unaudited)
�

Assets
�
�
�
Cash and cash equivalents
$
129,971

�
$
192,469

Accounts receivable, net
151,055

�
164,603

Inventories, net
209,418

�
197,661

Other current assets
66,515

�
68,243

�
�
Total current assets
556,959

�
622,976

Property, plant & equipment, net
311,999

�
271,437

Other assets
605,587

�
619,765

�
�
�
�
�
�
�
Total assets
$
1,474,545

�
$
1,514,178

�
�
�
�
�
�
Liabilities & Stockholders' Equity
�
�
�
Short-term debt & current maturities
$
1,655

�
$
45,630

Other current liabilities
163,401

�
171,298

�
�
Total current liabilities
165,056

�
216,928

Long-term debt
428,253

�
392,057

Other long-term liabilities
60,518

�
67,305

Stockholders' equity
820,718

�
837,888

�
�
�
�
�
�
�
Total liabilities & stockholders' equity
$
1,474,545

�
$
1,514,178






Free Cash Flow Reconciliation
(Data in thousands)
�
�
�
�
�
Three Months Ended
�
�
9/27/2014
�
9/28/2013
�
�
(unaudited)
GAAP cash flow from operations
�
$
31,242

�
$
29,360

�
�
�
�
�
Capital expenditures
�
(33,787
)
�
(15,110
)
Proceeds from sale of property, plant & equipment
�
313

�
73

Net investment in property, plant & equipment
�
(33,474
)
�
(15,037
)
�
�
�
�
�
Free cash flow after restructuring and transformation costs
�
(2,232
)
�
14,323

�
�
�
�
�
Restructuring and transformation costs
�
14,886

�
19,357

Tax benefit on restructuring and transformation costs
�
(5,461
)
�


Capital expenditures on VCC initiatives
�
20,199

�
1,286

�
�
�
�
�
Free cash flow before restructuring, transformation costs and VCC capital expenditures
�
$
27,392

�
$
34,966


�
�
Six Months Ended
�
�
9/27/2014
�
9/28/2013
�
�
(unaudited)
GAAP cash flow from operations
�
$
44,980

�
$
42,762

�
�
�
�
�
Capital expenditure
�
(70,872
)
�
(28,202
)
Proceeds from sale of property, plant & equipment
�
377

�
642

Net investment in property, plant & equipment
�
(70,495
)
�
(27,560
)
�
�
�
�
�
Free cash flow after restructuring and transformation costs
�
(25,515
)
�
15,202

�
�
�
�
�
Restructuring and transformation costs
�
33,824

�
31,505

Tax benefit on restructuring and transformation costs
�
(11,558
)
�


Capital expenditures on VCC initiatives
�
31,570

�
1,845

�
�
�
�
�
Free cash flow before restructuring, transformation costs and VCC capital expenditures
�
$
28,321

�
$
48,552





Haemonetics Corporation Financial Summary
Reconciliation of Non-GAAP Measures

Haemonetics has presented supplemental non-GAAP financial measures as part of this earnings release. A reconciliation is provided below that reconciles each non-GAAP financial measure with the most comparable GAAP measure. The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures. There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.
These measures are used by management to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are established based upon these non-GAAP measures. In the reconciliations below we have removed restructuring, transformation and other costs from our GAAP expenses. Our restructuring and transformation costs for the periods reported are principally related to:
"
Value Creation & Capture (VCC): employee severance and retention, product line transfer costs, accelerated depreciation and other costs associated with these initiatives, principally our manufacturing network optimization, but also including commercial excellence, productivity and other operating initiatives.
"
Whole Blood Acquisition: restructuring, integration and other transformation costs related to the August 1, 2012 acquisition of Pall's Transfusion Medicine Business.
"
In Process Research and Development: charges relate to the acquisition of certain technology and manufacturing rights to be used in a next generation device and related costs.
Restructuring and transformation costs also include costs related to activities launched prior to the VCC initiatives designed to align our cost structure with strategic and operational priorities. Costs incurred under these programs are reflected in "Productivity and operational initiatives" within the tables below.
We are reporting adjusted earnings before deal amortization, in addition to restructuring and transformation costs.
We believe this information is useful to investors because it allows for an evaluation of the Company with a focus on the performance of our core operations.




Reconciliation of Non-GAAP Measures for the Second Quarter of FY15 and FY14
(Data in thousands)
�
�
�
�
�
Three Months Ended
�
9/27/2014
�
9/28/2013
�
(unaudited)
Non-GAAP gross profit

�

GAAP gross profit
$
108,114

�
$
119,884

Restructuring and transformation costs
2,929

�
3,497

Non-GAAP gross profit
$
111,043

�
$
123,381

�
�
�
�
Non-GAAP R&D
�
�
GAAP R&D
$
10,938

�
$
14,946

Restructuring and transformation costs
(1,017
)
�
(4,358
)
Non-GAAP R&D
$
9,921

�
$
10,588

�
�
�
Non-GAAP S,G&A

�

GAAP S,G&A
$
84,769

�
$
81,508

Restructuring and transformation costs
(11,164
)
�
(10,828
)
Deal amortization
(7,627
)
�
(6,893
)
Non-GAAP S,G&A
$
65,978

�
$
63,787

�
�
�
�
Non-GAAP operating expenses


�


GAAP operating expenses
$
95,707

�
$
96,454

Restructuring and transformation costs
(12,181
)
�
(15,186
)
Deal amortization
(7,627
)
�
(6,893
)
Non-GAAP operating expenses
$
75,899

�
$
74,375

�
�
�
�
Non-GAAP operating income


�


GAAP operating income
$
12,407

�
$
23,430

Restructuring and transformation costs
15,110

�
18,683

Deal amortization
7,627

�
6,893

Non-GAAP operating income
$
35,144

�
$
49,006

�
�
�
�
Non-GAAP other expense

�

GAAP other expense
$
2,645

�
$
2,542

Restructuring and transformation costs
(235
)
�
(189
)
Non-GAAP other expense
$
2,410

�
$
2,353

�
�
�
�
Non-GAAP income before taxes


�


GAAP income before taxes
$
9,762

�
$
20,888

Restructuring and transformation costs
15,345

�
18,872

Deal amortization
7,627

�
6,893

Non-GAAP income before taxes
$
32,734

�
$
46,653

�
�
�
�
Non-GAAP net income


�


GAAP net income
$
7,487

�
$
16,548

Restructuring and transformation costs
15,345

�
18,872

Deal amortization
7,627

�
6,893

Tax benefit associated with non-GAAP adjustments
(6,127
)
�
(7,892
)
Non-GAAP net income
$
24,332

�
$
34,421

�
�
�
�



Non-GAAP net income per common share assuming dilution

�

GAAP net income per common share
$
0.14

�
$
0.32

Non-GAAP items after tax per common share assuming dilution
$
0.33

�
$
0.34

Non-GAAP net income per common share assuming dilution
$
0.47

�
$
0.66

Presented below are additional Constant Currency performance measures. We measure different components of our business at constant currency. We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates. These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of 0.833 Euro to 1.00 US Dollar and 110 Yen to 1.00 US Dollar. They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K.
�
�
�
�
�
Three Months Ended
�
9/27/2014
�
9/28/2013
�
(unaudited)
Non-GAAP revenues


�


GAAP revenue
$
227,580

�
$
235,755

Foreign currency effects
(8,821
)
�
(11,215
)
Non-GAAP revenue - constant currency
$
218,759

�
$
224,540

�
�
�
�
Non-GAAP net income

�

Non-GAAP net income, adjusted for restructuring and transformation costs and deal amortization
$
24,332

�
$
34,421

Foreign currency effects
(2,516
)
�
(5,373
)
Income tax associated with foreign currency effects
645

�
1,409

Non-GAAP net income - constant currency
$
22,461

�
$
30,457

�
�
�
�
Non-GAAP net income per common share assuming dilution

�

Non-GAAP net income per common share assuming dilution, adjusted for restructuring and transformation costs and deal amortization
$
0.47

�
$
0.66

Foreign currency effects after tax per common share assuming dilution
$
(0.04
)
�
$
(0.08
)
Non-GAAP net income per common share assuming dilution - constant currency
$
0.43

�
$
0.58






Reconciliation of Non-GAAP Measures for FY15 and FY14
(Data in thousands)
�
�
�
�
�
Six Months Ended
�
9/27/2014
�
9/28/2013
�
(unaudited)
Non-GAAP gross profit

�

GAAP gross profit
$
214,392

�
$
231,295

Restructuring and transformation costs
5,287

�
5,600

Non-GAAP gross profit
$
219,679

�
$
236,895

�

�

Non-GAAP R&D

�
GAAP R&D
$
26,319

�
$
26,155

Restructuring and transformation costs
(4,580
)
�
(5,303
)
Non-GAAP R&D
$
21,739

�
$
20,852

�

�
Non-GAAP S,G&A

�

GAAP S,G&A
$
177,331

�
$
188,318

Restructuring and transformation costs
(28,012
)
�
(41,176
)
Deal amortization
(15,301
)
�
(13,612
)
Non-GAAP S,G&A
$
134,018

�
$
133,530

�

�

Non-GAAP operating expenses


�


GAAP operating expenses
$
203,650

�
$
214,473

Restructuring and transformation costs
(32,592
)
�
(46,479
)
Deal amortization
(15,301
)
�
(13,612
)
Non-GAAP operating expenses
$
155,757

�
$
154,382

�

�

Non-GAAP operating income


�


GAAP operating income
$
10,742

�
$
16,822

Restructuring and transformation costs
37,879

�
52,079

Deal amortization
15,301

�
13,612

Non-GAAP operating income
$
63,922

�
$
82,513



�

Non-GAAP other expense

�

GAAP other expense
$
5,188

�
$
5,183

Restructuring and transformation costs
(459
)
�
(310
)
Non-GAAP other expense
$
4,729

�
$
4,873

�

�

Non-GAAP income before taxes


�


GAAP income before taxes
$
5,554

�
$
11,639

Restructuring and transformation costs
38,338

�
52,389

Deal amortization
15,301

�
13,612

Non-GAAP income before taxes
$
59,193

�
$
77,640

�

�

Non-GAAP net income


�


GAAP net income
$
3,839

�
$
8,674

Restructuring and transformation costs
38,338

�
52,389

Deal amortization
15,301

�
13,612

Tax benefit associated with non-GAAP adjustments
(13,385
)
�
(16,515
)
Non-GAAP net income
$
44,093

�
$
58,160




�





Non-GAAP net income per common share assuming dilution

�

GAAP net income per common share
$
0.07

�
$
0.17

Non-GAAP items after tax per common share assuming dilution
$
0.78

�
$
0.94

Non-GAAP net income per common share assuming dilution
$
0.85

�
$
1.11

Presented below are additional Constant Currency performance measures. We measure different components of our business at constant currency. We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates. These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of 0.833 Euro to 1.00 US Dollar and 110 Yen to 1.00 US Dollar. They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K.
�
�
�
�
�
Six Months Ended
�
9/27/2014
�
9/28/2013
�
(unaudited)
Non-GAAP revenues


�


GAAP revenue
$
452,068

�
$
455,297

Foreign currency effects
(17,970
)
�
(20,389
)
Non-GAAP revenue - constant currency
$
434,098

�
$
434,908

�


�


Non-GAAP net income

�

Non-GAAP net income, adjusted for restructuring and transformation costs and deal amortization
$
44,093

�
$
58,160

Foreign currency effects
(5,916
)
�
(10,569
)
Income tax associated with foreign currency effects
1,509

�
2,652

Non-GAAP net income - constant currency
$
39,686

�
$
50,243

�


�


Non-GAAP net income per common share assuming dilution

�

Non-GAAP net income per common share assuming dilution, adjusted for restructuring and transformation costs and deal amortization
$
0.85

�
$
1.11

Foreign currency effects after tax per common share assuming dilution
$
(0.09
)
�
$
(0.15
)
Non-GAAP net income per common share assuming dilution - constant currency
$
0.76

�
$
0.96






Restructuring, Transformation and Other Costs
(Data in thousands)
GAAP results include the following items which are excluded from adjusted results.
�
�
�
Three Months Ended
�
9/27/2014
�
9/28/2013
�
(unaudited)
Manufacturing network optimization
$
9,987

�
$
5,708

Commercial excellence initiatives
1,492

�
2,008

Productivity and operational initiatives
1,921

�
462

Accelerated depreciation, asset write-down and other non-cash items
884

�
2,912

Whole blood acquisition and integration


�
3,256

In process research and development and related costs
250

�
3,976

Market-based stock compensation
811

�
550

Total restructuring, transformation and other costs
$
15,345

�
$
18,872

�
Six Months Ended
�
9/27/2014
�
9/28/2013
�
(unaudited)
Manufacturing network optimization
$
22,764

�
$
27,893

Commercial excellence initiatives
5,768

�
4,165

Productivity and operational initiatives
4,729

�
1,113

Accelerated depreciation, asset write-down and other non-cash items
1,714

�
4,458

Whole blood acquisition and integration


�
10,234

In process research and development and related costs
1,796

�
3,976

Market-based stock compensation
1,567

�
550

Total restructuring, transformation and other costs
$
38,338

�
$
52,389

�
�
�
�
Deal Amortization
(Data in thousands)
GAAP results include the following item which is excluded from adjusted results.
�
Three Months Ended
�
9/27/2014
�
9/28/2013
�
(unaudited)
Deal amortization
$
7,627

�
$
6,893

�
Six Months Ended
�
9/27/2014
�
9/28/2013
�
(unaudited)
Deal amortization
$
15,301

�
$
13,612





Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings